Lutetium-177 Market Size, Share & Trends Analysis Report By Product (High Specific Activity Lutetium-177, General Lutetium-177), By Applications (Nuclear Therapy, Diagnosis, Others), By End Use, By Region, and Segment Forecasts - 2035

Lutetium-177 Market Overview

The lutetium-177 market size was valued at USD 125.8 million in 2025 and is poised to grow from USD 156.24 million in 2026 to USD 1098.88 million by 2035, growing at a CAGR of 24.2% during the forecast period (2026-2035).

The Lutetium-177 market is entering a high-growth phase as targeted radioligand therapy moves into earlier stages of cancer treatment and pharmaceutical manufacturers expand isotope-processing capacity. Lutetium-177 has a physical half-life of approximately 6.65 days, making coordinated reactor production, purification, radiolabeling, quality control and rapid distribution essential. High Specific Activity Lutetium-177 is receiving particularly strong attention because no-carrier-added production can provide substantially higher specific activity than conventional direct reactor routes. Research published in 2026 highlighted approximately 4 TBq per mg achievable through an indirect ytterbium-based route compared with around 0.5 TBq per mg under representative direct-production conditions. This performance advantage is strengthening demand from developers of precision radiopharmaceuticals targeting prostate cancer, neuroendocrine tumors and investigational solid-tumor indications. Market expansion is also being reinforced by broader hospital adoption of theranostics, increasing availability of molecular imaging and investment in specialized radiopharmacy infrastructure capable of handling therapeutic radioisotopes.

The United States remains one of the most important Lutetium-177 markets because of rapid regulatory adoption of targeted radioligand therapies, expanding treatment-center capacity and major investments in domestic manufacturing. In July 2026, the approved use of lutetium Lu 177 vipivotide tetraxetan was expanded into PSMA-positive metastatic hormone-sensitive prostate cancer in combination with androgen receptor pathway inhibitor therapy. The supporting Phase 3 program randomized 1,144 patients, including 572 patients in each treatment arm, demonstrating the scale at which Lutetium-177 therapies are moving into mainstream oncology. Earlier expansion in March 2025 had already widened eligibility for patients with metastatic castration-resistant prostate cancer before chemotherapy, based on a 468-patient trial. U.S. manufacturing capacity has consequently become strategically important, with large radioligand facilities designed to support hundreds of thousands of annual therapeutic doses and reduce exposure to transatlantic delivery disruptions.

• 

  Download Free sample to learn more about this report.

Key Findings

• Leading Product Type: High Specific Activity Lutetium-177 is expected to lead demand as no-carrier-added production can achieve approximately 4 TBq per mg under suitable manufacturing conditions, supporting highly concentrated targeted radiopharmaceutical formulations.
• Leading Application: Nuclear Therapy is projected to dominate consumption as approved Lutetium-177 prostate cancer regimens can involve 6 treatment doses administered at approximately 6-week intervals, creating recurring isotope requirements per eligible patient.
• Leading Region: North America is expected to retain the largest regional position with an estimated 42% market share, supported by accelerated radioligand adoption, expanded indications and growing domestic isotope-processing and treatment infrastructure.
• Fastest Growing Region: Asia-Pacific is projected to expand fastest and account for approximately 25% of global demand by the middle of the forecast period as nuclear medicine capacity expands across major healthcare systems.
• Technology Trend: No-carrier-added production is becoming a major technology direction because indirect ytterbium irradiation can generate Lutetium-177 with specific activity near 4 TBq per mg while limiting long-lived isotope contamination.
• Market Driver: Earlier-line prostate cancer treatment is accelerating isotope requirements, with a major 2026 Phase 3 Lutetium-177 program involving 1,144 patients and demonstrating expanding clinical utilization beyond heavily pretreated populations.
• Competitive Landscape: Supply security is becoming a central competitive factor, illustrated by isotope producers reserving substantial reactor access, including agreements providing priority access to 50% of available irradiation capacity at selected facilities.
• Future Outlook: The market is moving toward diversified tumor targets, with investigational Lutetium-177 programs already extending beyond prostate and neuroendocrine cancers into indications where targeted antigens can exceed 90% tumor-expression prevalence.

Latest Trends

The most influential trend in the Lutetium-177 market is the migration of radioligand therapy from late-stage salvage treatment toward earlier disease settings. A major milestone occurred in July 2026 when Lutetium-177-based therapy combined with androgen receptor pathway inhibition gained authorization for PSMA-positive metastatic hormone-sensitive prostate cancer. Clinical evaluation included 1,144 randomized patients and demonstrated a statistically significant improvement in radiographic progression-free survival, with a hazard ratio of approximately 0.72. This development materially expands the addressable treatment population and changes isotope demand patterns because patients can enter radioligand therapy earlier and remain within treatment pathways for longer periods. The trend is prompting nuclear medicine departments to add treatment slots, radiation-safety procedures and trained personnel while manufacturers establish geographically distributed production plants capable of supplying short-lived products reliably.

A second major trend is the shift toward High Specific Activity Lutetium-177 produced through no-carrier-added processes. Manufacturers and radiopharmaceutical developers increasingly prefer isotope characteristics that permit high molar activity and efficient labeling of targeting molecules without excessive stable lutetium. Lutetium-177 has a half-life near 6.65 days, while the undesirable long-lived Lutetium-177m impurity has a half-life of roughly 160 days, making production-route optimization commercially significant. Indirect production using enriched ytterbium-176 is therefore attracting investment despite additional separation complexity. The technology is also supporting new antibody, peptide and small-molecule radiopharmaceutical programs. In one emerging glioblastoma program, a Lutetium-177-labeled antibody fragment has been evaluated across 10 patients at 4 German clinical sites, illustrating how next-generation development is broadening Lutetium-177 beyond established oncology categories.

Market Dynamics

Driver

""Earlier use of targeted radioligand therapy is rapidly increasing isotope demand.""

Expanding clinical eligibility for targeted radioligand therapy is the strongest driver of the Lutetium-177 market. Lutetium-177 medicines were initially concentrated in relatively advanced cancer populations, but regulatory and clinical developments are progressively moving treatment earlier in the disease pathway. The March 2025 U.S. expansion of Lutetium-177 therapy into pre-chemotherapy metastatic castration-resistant prostate cancer followed a randomized study of 468 patients and showed median radiographic progression-free survival of approximately 9.3 months compared with 5.6 months for the comparator treatment under the primary analysis. The recommended regimen uses approximately 7.4 GBq per administration every 6 weeks for as many as 6 doses. Each additional eligible patient therefore represents repeated demand for precisely manufactured radioisotope, formulated radiopharmaceutical doses, diagnostic imaging and specialized hospital infrastructure. Wider adoption is creating a multiplier effect across isotope producers, radiopharmaceutical manufacturers, logistics providers and oncology treatment centers.

Clinical expansion accelerated again during 2026 when Lutetium-177-based therapy entered PSMA-positive metastatic hormone-sensitive prostate cancer. The pivotal Phase 3 program randomized 572 patients to the Lutetium-177 combination arm and 572 to the comparison arm, demonstrating the much larger scale now being addressed by radioligand therapy. As indications move earlier, manufacturers need to manage higher order volumes while hospitals must increase nuclear medicine throughput and radiation-protection capacity. Prostate cancer remains the central commercial demand generator, but parallel development in neuroendocrine tumors and other solid tumors is widening the potential treatment base. Consequently, the Lutetium-177 supply chain is increasingly being planned as an industrial-scale pharmaceutical manufacturing network rather than a limited nuclear-medicine specialty, which supports sustained market growth throughout the forecast period.

Restraint

""Short isotope life and complex manufacturing requirements constrain reliable global distribution.""

The principal restraint is the operational complexity created by radioactive decay, reactor dependence and tightly controlled pharmaceutical production. Lutetium-177 has a half-life of approximately 6.65 days, meaning usable activity begins declining immediately after production and continues throughout purification, formulation, quality release, transportation and hospital scheduling. Conventional isotope manufacturing also depends heavily on a relatively small network of qualified research reactors and specialized processing installations. Unexpected reactor maintenance, production failures, weather interruptions or transport delays can therefore disrupt treatment schedules. Historical supply constraints demonstrated that concentration of commercial output at a limited number of facilities can expose healthcare providers to cancellations and rescheduling. Producers are addressing this weakness through redundant manufacturing sites, but establishing each new radiopharmaceutical facility requires validated clean rooms, radiation shielding, regulatory approval and qualified technical teams, significantly increasing market-entry complexity.

The challenge is greater for High Specific Activity Lutetium-177 because no-carrier-added production normally requires enriched ytterbium-176, neutron irradiation and sophisticated chemical separation. Although indirect production can generate specific activity around 4 TBq per mg under suitable reactor conditions, it produces less initial Lutetium-177 than the direct route and demands efficient recovery of costly target material. Direct irradiation can offer comparatively straightforward production but may provide specific activity around 0.5 TBq per mg under representative commercial-reactor conditions and can introduce long-lived Lutetium-177m. Because Lutetium-177m has an approximately 160-day half-life, waste handling and downstream processing become important operational considerations. These technical differences limit the number of producers capable of delivering GMP-grade isotope consistently and make supply diversification slower than underlying therapeutic demand growth.

Opportunity

""New tumor targets and regional production networks are opening substantial expansion opportunities.""

The largest opportunity lies in expanding Lutetium-177 into additional tumor types through new ligands, peptides and antibody-based targeting platforms. The success of PSMA-directed treatment has validated the therapeutic principle of delivering beta radiation directly to antigen-expressing cancer cells, encouraging developers to evaluate targets in gastrointestinal, neurological and other solid tumors. One investigational glioblastoma approach uses a Lutetium-177-labeled antibody fragment against carbonic anhydrase XII, a surface target reported in more than 90% of glioblastoma cases. Its early clinical study enrolled 10 patients at 4 specialized hospitals. Similar programs can increase future demand for High Specific Activity Lutetium-177 because antibody fragments and other precision targeting molecules may benefit from high molar activity. Successful expansion beyond prostate cancer could substantially diversify market demand and reduce reliance on a single therapeutic category.

Regional manufacturing expansion presents another major opportunity because Lutetium-177 economics favor production close to treatment centers. Research published in 2026 estimated that annual isotope requirements associated with approximately 15,000 prostate cancer patients could theoretically be supported by one pressurized water reactor under a defined ytterbium irradiation configuration involving 200 grams of enriched target material irradiated for 2 weeks across 17 cycles annually. Although commercial implementation requires extensive regulatory and pharmaceutical qualification, the analysis demonstrates the potential for countries with suitable reactor infrastructure to develop domestic supply chains. Asia-Pacific, the Middle East and selected European markets are therefore investing in nuclear medicine capacity, while established producers seek new irradiation partnerships that can increase resilience and reduce dependence on a limited number of reactors.

Challenge

""Scaling pharmaceutical-grade isotope output without compromising quality remains difficult.""

The primary challenge is scaling manufacturing quickly enough to match accelerating clinical utilization while maintaining pharmaceutical-grade specifications. Lutetium-177 producers must coordinate neutron irradiation, isotope separation, sterile processing and shipment within a narrow period dictated by the approximately 6.65-day half-life. Treatment regimens may require up to 6 administrations per patient, creating recurring demand that must be synchronized with hospital appointments. High-volume commercialization also magnifies quality-control requirements because each batch must meet radionuclidic, chemical and microbiological specifications before release. Even companies with advanced therapeutic pipelines can encounter manufacturing and facility-related regulatory barriers. In August 2026, one advanced Lutetium-177 therapy application received a regulatory Complete Response Letter focused on chemistry, manufacturing and controls and third-party facility inspection matters rather than clinical efficacy, underscoring how manufacturing readiness can directly affect commercialization timelines.

A parallel challenge involves building sufficient specialized clinical infrastructure to administer the therapies generated by growing isotope supply. Radioligand treatment requires licensed nuclear medicine personnel, radiation-protection procedures, dose-storage areas and coordination with diagnostic imaging. A standard prostate cancer regimen can involve approximately 7.4 GBq per treatment session, meaning providers must operate within strict radiation-handling rules. Treatment-center capacity can therefore become a bottleneck even when isotope production expands. Companies are responding by establishing more geographically distributed manufacturing plants and supporting treatment-center networks, but the full ecosystem must scale together. The market's projected 24.2% CAGR through 2035 will require isotope producers, radiopharmacies, hospitals, regulators and logistics companies to increase capacity in parallel rather than relying on manufacturing expansion alone.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

The Lutetium-177 market is segmented by product type into High Specific Activity Lutetium-177 and General Lutetium-177 and by application into Nuclear Therapy, Diagnosis and Others. High Specific Activity Lutetium-177 is gaining importance because emerging radiopharmaceutical programs increasingly require high molar activity, low stable-metal content and precise radiolabeling performance. Nuclear Therapy remains the principal application, supported by treatment protocols that can involve 6 administered doses per eligible patient. Diagnosis represents a smaller share because Lutetium-177 is primarily valued for beta-emitting therapeutic applications, although its gamma emissions can facilitate post-treatment imaging and dosimetric assessment. The segmentation structure is therefore shifting progressively toward advanced therapeutic usage and specialized high-purity isotope production.

By Types

High Specific Activity Lutetium-177: High Specific Activity Lutetium-177 is estimated to account for approximately 63% of market demand and is expected to increase its share during the forecast period as targeted radiopharmaceutical developers prioritize no-carrier-added isotope. Indirect production through enriched ytterbium-176 can achieve specific activity close to 4 TBq per mg under optimized conditions, substantially above representative direct-production values. High activity per unit mass improves labeling flexibility for peptides, antibody fragments and other targeting molecules in which excessive stable lutetium could reduce binding efficiency. The segment also benefits from lower Lutetium-177m contamination in properly designed no-carrier-added production routes, which simplifies certain downstream radioactive-waste considerations. Growing clinical pipelines and supply agreements centered specifically on no-carrier-added isotope are consequently strengthening this segment's strategic position.

General Lutetium-177: General Lutetium-177 is estimated to represent approximately 37% of market demand and continues to serve established radiopharmaceutical manufacturing requirements where conventional specific activity is acceptable. Direct neutron irradiation of enriched lutetium-176 can provide strong production yield and relatively straightforward processing compared with indirect ytterbium separation. Under representative commercial reactor conditions, specific activity may be around 0.5 TBq per mg, making the material suitable for selected formulations while generally providing lower molar activity than no-carrier-added alternatives. The segment remains important because direct production can support large batch volumes and geographically diversified isotope supply. However, growing preference for high-specific-activity products and concerns surrounding long-lived Lutetium-177m impurities are expected to gradually moderate its market share through 2035.

By Applications

Nuclear Therapy: Nuclear Therapy dominates the Lutetium-177 market with an estimated 86% share because the isotope is primarily used as a therapeutic beta emitter in targeted radiopharmaceuticals. Approved prostate cancer therapy commonly uses approximately 7.4 GBq per intravenous dose at intervals of around 6 weeks for up to 6 administrations. The therapeutic segment is expanding as Lutetium-177 moves into earlier prostate cancer settings and continues to support neuroendocrine tumor management. Clinical development is additionally extending into glioblastoma and other solid tumors through new targeting agents. The combination of established commercial products, expanded indications and a growing pipeline gives Nuclear Therapy a substantially larger isotope requirement than other applications.

Diagnosis: Diagnosis accounts for an estimated 9% share of Lutetium-177 utilization. Although Lutetium-177 is not primarily a diagnostic radionuclide, its gamma emissions allow imaging after administration and can support verification of biodistribution, treatment planning and dosimetric assessment. The approximately 6.65-day half-life provides sufficient time for therapeutic administration and follow-up imaging while remaining practical for clinical radiopharmacy workflows. Demand is increasing alongside personalized dosimetry approaches that use imaging data to estimate radiation deposition in tumors and healthy organs. The segment remains substantially smaller than Nuclear Therapy because dedicated diagnostic radioisotopes are generally preferred for initial patient selection, particularly PET agents used to identify suitable molecular targets before Lutetium-177 treatment.

Others: Others represent an estimated 5% of market demand and include research, radiopharmaceutical development, preclinical testing, calibration and specialized academic applications connected with Lutetium-177. Investigational programs increasingly consume GMP-grade isotope during Phase 1 through Phase 3 development, while university laboratories evaluate new targeting molecules and dosimetry methodologies. An advanced neuroendocrine tumor study has involved 309 patients, demonstrating how clinical development programs themselves can create meaningful isotope requirements before full commercialization. Research usage remains comparatively small but strategically important because successful experimental radiopharmaceuticals can later transition into much larger Nuclear Therapy demand. The segment is expected to remain near 5% as therapeutic commercialization expands faster than research consumption.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

North America

North America is estimated to account for approximately 42% of the Lutetium-177 market, making it the leading regional market. The United States is the main contributor because of broad PSMA-PET availability, established nuclear medicine centers, strong reimbursement pathways for approved radioligand therapies and continued investment in manufacturing. The March 2025 expansion of Lutetium-177 therapy into pre-chemotherapy metastatic castration-resistant prostate cancer materially increased eligible patients, while the July 2026 approval in metastatic hormone-sensitive disease expanded treatment even further. The 2026 pivotal study included 1,144 participants, reflecting the increasing scale of clinical adoption. Large academic cancer centers and community nuclear medicine networks are consequently adding infusion capacity and specialized radiation-management workflows.

Regional supply security has improved through investment in domestic radioligand production. A major Indianapolis facility covering approximately 70,000 square feet was designed as a large-scale manufacturing center and contributed to planned radioligand production capacity reaching approximately 250,000 doses annually from 2024 onward. By 2026, additional U.S. facilities were operational or under construction, creating a network of 5 manufacturing sites connected with radioligand therapy expansion. This distributed model reduces dependence on international transportation and improves dose delivery reliability within the Lutetium-177 half-life window of approximately 6.65 days. Canada is also expanding radiopharmaceutical research and nuclear medicine usage, supporting additional regional demand for both High Specific Activity Lutetium-177 and General Lutetium-177.

Europe

Europe holds an estimated 31% share of the Lutetium-177 market and remains a major center for isotope manufacturing, reactor irradiation, radiopharmaceutical development and clinical nuclear medicine. Germany, France, Italy, the Netherlands, Switzerland, Turkey and the United Kingdom support established research and commercial ecosystems. European producers have developed long-term relationships with research reactors to secure consistent neutron irradiation. In June 2025, a major isotope manufacturer renewed a collaboration that provides priority access to approximately 50% of available irradiation capacity at a high-flux European reactor for no-carrier-added Lutetium-177 production. Such agreements are strategically important because treatment demand increasingly requires predictable weekly production schedules and rapid transportation across multiple countries.

European therapeutic adoption is also expanding through regulatory changes and clinical research. The United Kingdom authorized earlier use of Lutetium-177 therapy for eligible metastatic castration-resistant prostate cancer patients in February 2026 following evidence of a 59% reduction in the risk of radiographic progression or death in the supporting study. At the same time, European developers are advancing new no-carrier-added Lutetium-177 products. A Phase 3 neuroendocrine tumor program enrolling 309 patients reported improved progression-free survival relative to its comparator and progressed into regulatory review. Germany remains particularly important because it combines isotope manufacturing expertise with advanced clinical research and university nuclear medicine centers, helping Europe maintain a strong position in both commercial supply and therapeutic innovation.

Asia-Pacific

Asia-Pacific represents an estimated 19% of the Lutetium-177 market and is expected to record the fastest regional expansion as cancer incidence, nuclear medicine investment and domestic isotope-production initiatives increase. Japan, China, South Korea, Australia and India are expanding capabilities for targeted radionuclide therapy, while major hospitals are developing theranostic programs combining molecular imaging with therapeutic isotopes. Japan provides an example of emerging production interest: a 2026 technical assessment evaluated the possibility of manufacturing no-carrier-added Lutetium-177 using commercial pressurized water reactors. Under the modeled scenario, annual demand corresponding to approximately 15,000 prostate cancer patients could be addressed using one reactor with repeated enriched ytterbium irradiation cycles.

The regional opportunity is strengthened by the large patient population and increasing availability of PET imaging required for molecular selection. Domestic manufacturing could reduce reliance on European isotope shipments, which is particularly valuable because Lutetium-177 activity declines continuously over its approximately 6.65-day half-life. India is expanding nuclear medicine installations in metropolitan hospitals, while China is investing in radiopharmaceutical manufacturing, isotope infrastructure and precision oncology. Australia also has a well-established nuclear medicine research environment. Asia-Pacific's share is expected to move progressively above its current 19% position as treatment-center capacity rises and locally produced Lutetium-177 becomes more widely available during the forecast period.

Middle East & Africa

The Middle East & Africa accounts for an estimated 8% of global Lutetium-177 market demand. The region remains smaller than North America, Europe and Asia-Pacific but is developing rapidly around specialized hospitals and nuclear medicine centers in Turkey, the United Arab Emirates, Saudi Arabia, Egypt and selected South African locations. Turkey has particular strategic relevance because a major regional radiopharmaceutical producer operates within an international network spanning more than 70 countries and approximately 13 facilities. That distribution footprint supports isotope availability across markets where domestic reactor capacity and radiopharmacy infrastructure remain limited. Increasing prostate cancer diagnosis and hospital investment are creating further demand for therapeutic radiopharmaceuticals.

Regional growth is constrained by uneven access to PSMA-PET imaging, specialized radiopharmacy services and qualified nuclear medicine personnel. Lutetium-177 treatments can involve individual activities near 7.4 GBq, requiring licensed facilities and rigorous radiation-protection systems. Nevertheless, demand is increasing because major healthcare systems in Gulf countries are investing in oncology centers designed to reduce dependence on overseas treatment. North African markets are also expanding nuclear medicine applications, particularly in Egypt. The Middle East & Africa is therefore expected to gradually increase its participation through technology transfer, imported isotope supply and localized radiopharmaceutical preparation while maintaining an estimated single-digit share during the near-term forecast period.

List of Top Lutetium-177 Companies

• Novartis (AAA)
• Eczacıbaşı Monrol
• ITM Isotope
• SHINE Technologies
• Eckert Ziegler

Top 2 Companies Market Share

Novartis (AAA): Novartis holds an estimated 32% position within the commercially relevant Lutetium-177 ecosystem when isotope consumption associated with its approved radioligand therapies and integrated manufacturing footprint is considered. The company's scale increased significantly after indications expanded during 2025 and 2026, while a network of 5 U.S. manufacturing facilities operational or under development strengthens supply resilience. Its established prostate cancer franchise creates sustained Lutetium-177 consumption because standard treatment can involve up to 6 administrations per patient.

ITM Isotope: ITM Isotope is estimated to hold approximately 21% of specialized Lutetium-177 supply activity, supported by its focus on GMP-grade no-carrier-added isotope and vertically integrated radiopharmaceutical development. The company has maintained isotope-production operations since 2004 and has secured long-term access to enriched ytterbium-176 and high-flux reactor irradiation. A renewed 2025 agreement secured priority access to approximately half of available irradiation capacity at a European reactor, strengthening its ability to supply High Specific Activity Lutetium-177 to commercial and clinical partners.

Investment Analysis

Investment in the Lutetium-177 market is increasingly directed toward manufacturing redundancy, reactor access, enriched isotope inventories and distributed radiopharmaceutical production. The approximately 6.65-day physical half-life makes a multi-site operating model financially and strategically preferable to highly centralized production because geographic proximity improves usable activity at delivery. Major manufacturers have therefore invested in large radioligand facilities and multiple regional sites. One U.S. manufacturing expansion included a facility of approximately 70,000 square feet designed to support high-throughput therapeutic dose production. Investors are also focusing on no-carrier-added isotope technology because high specific activity near 4 TBq per mg can support next-generation radiopharmaceuticals requiring low metal mass and efficient molecular labeling.

Capital is also moving into therapeutic pipelines that create captive Lutetium-177 demand. The commercial success of prostate-focused radioligand therapy has encouraged companies to fund candidates directed at neuroendocrine tumors, glioblastoma and other antigen-positive solid tumors. One advanced Lutetium-177 neuroendocrine tumor Phase 3 study enrolled 309 patients, while a glioblastoma program has evaluated 10 patients across 4 hospitals. These development programs require reliable GMP isotope supply years before potential commercialization, increasing the attractiveness of long-term supply agreements and vertically integrated production. Investment opportunities are therefore distributed across reactors, isotope separation, enriched ytterbium recycling, sterile manufacturing, radiopharmacies, logistics and hospital treatment infrastructure rather than being concentrated only in drug development.

New Product Development

New product development is centered on improving targeting specificity, isotope purity and treatment convenience. High Specific Activity Lutetium-177 is increasingly paired with peptides, small molecules and antibody fragments designed to bind tumor-associated targets while limiting irradiation of healthy tissue. In prostate cancer, PSMA-targeted therapy has demonstrated the commercial viability of this approach and opened opportunities for next-generation molecules optimized for tumor retention and renal clearance. Development is also spreading into neurological malignancies. One investigational Lutetium-177 antibody fragment targeting carbonic anhydrase XII has entered clinical evaluation in glioblastoma, where the target is reported on more than 90% of tumor cases. Such programs broaden potential utilization beyond current leading indications.

Product development is also improving personalized dosimetry and manufacturing compatibility. Developers are assessing standardized imaging time points, dose calculations and simplified treatment workflows that could make radioligand therapy easier for hospitals to administer. A 2026 advanced neuroendocrine tumor program evaluated approaches supporting single-timepoint dosimetry, which could reduce the operational burden associated with multiple imaging visits. Simultaneously, isotope suppliers are refining purification processes to reduce stable-metal content and long-lived Lutetium-177m contamination. Because Lutetium-177m has an approximately 160-day half-life, minimizing this impurity can simplify waste management and downstream pharmaceutical processing. These manufacturing improvements are expected to reinforce adoption of High Specific Activity Lutetium-177 in future precision-oncology products.

Five Recent Developments

• August 2026: ITM Isotope entered a Lutetium-177 supply agreement supporting development of a targeted antibody-radionuclide candidate for CD44v6-positive solid tumors. The agreement provides no-carrier-added isotope for an ongoing clinical program and expands commercial interest beyond the 2 most established Lutetium-177 oncology categories.
• July 2026: A major Lutetium-177 prostate cancer therapy received an expanded U.S. indication for PSMA-positive metastatic hormone-sensitive disease. The supporting Phase 3 program randomized 1,144 patients and moved radioligand treatment into a substantially earlier stage of metastatic prostate cancer management.
• July 2026: ITM reported Phase 3 results for no-carrier-added Lutetium-177 edotreotide in advanced gastroenteropancreatic neuroendocrine tumors. The randomized program enrolled 309 patients and strengthened clinical evidence supporting expansion of high-specific-activity Lutetium-177 therapies beyond prostate cancer.
• March 2025: Curium completed its acquisition of Eczacıbaşı Monrol, combining broader nuclear medicine capabilities with additional Lutetium-177 manufacturing capacity. Monrol's international footprint extends across more than 70 countries and includes approximately 13 facilities supporting radiopharmaceutical distribution and production.
• January 2024: A large U.S. radioligand manufacturing facility became commercially approved for Lutetium-177-based medicine production. The approximately 70,000-square-foot site contributed to manufacturing capacity planned at roughly 250,000 radioligand doses annually and strengthened domestic supply resilience.

Report Coverage

The Lutetium-177 market report covers market conditions from 2025 through 2035 and evaluates the industry across product type, application, regional demand, manufacturing trends, investment and competitive activity. The analysis incorporates the supplied market trajectory from USD 125.8 million in 2025 to USD 156.24 million in 2026 and USD 1098.88 million by 2035, representing a 24.2% CAGR. Product coverage is limited to High Specific Activity Lutetium-177 and General Lutetium-177, while application analysis covers Nuclear Therapy, Diagnosis and Others. The report examines how isotope half-life, reactor availability, no-carrier-added production, radionuclidic purity, clinical approvals and radiopharmaceutical manufacturing capacity shape commercial adoption.

The competitive assessment focuses on Novartis (AAA), Eczacıbaşı Monrol, ITM Isotope, SHINE Technologies and Eckert Ziegler and evaluates their roles across isotope production, radiopharmaceutical development, manufacturing expansion and supply security. Regional analysis allocates an estimated 42% share to North America, 31% to Europe, 19% to Asia-Pacific and 8% to the Middle East & Africa, totaling 100%. The report additionally evaluates therapeutic protocols involving approximately 7.4 GBq per administration, treatment schedules reaching 6 doses and technical differentiation between production routes capable of approximately 0.5 TBq per mg and high-specific-activity processes approaching 4 TBq per mg. Coverage reflects the accelerating shift toward precision radioligand oncology, broader tumor targets and geographically diversified Lutetium-177 manufacturing.